Barclays’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Barclays’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24	Closed	–	–	7118
2019 Q3	$0	Buy	+24	New	+$219	﹤0.01%	7391
2018 Q2	–	Sell	-4	Closed	–	–	7478
2018 Q1	$0	Buy	+4	New	+$127	﹤0.01%	7505

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Barclays's BLPH Position: Q4 2019 in Review

Barclays sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2019, closing a stake of 24 shares.

Barclays first reported a position in BLPH in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2019. 19 funds tracked by Wall St. Rank hold BLPH as of Q4 2019.

Barclays reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Barclays sold 24 Bellerophon Therapeutics, Inc. shares in Q4 2019.
Barclays first reported a position in Bellerophon Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
Barclays's Bellerophon Therapeutics, Inc. position peaked at $0 in Q3 2019.
19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.